Subjects were distributed using a CV risk prediction model developed using an independent dataset from the LEADER CVOT, which evaluated CV outcomes with liraglutide vs placebo
Thus, in perfect agreement with the recent ADA-EASD consensus report [6], we also encourage the adoption of GLP-1RA plus SGLT2i combination therapy in T2DM patients with established ASCVD (coronary artery disease, cerebrovascular disease, or peripheral arterial disease) or multiple risk factors for ASCVD (i.e., age 55 years, obesity, dyslipidemia, hypertension, current tobacco use, left ventricular hypertrophy, and/or proteinuria) whose HbA1c remains suboptimal despite initial treatment with only one of these agents
Semaglutide has been heralded as a potentially even more potent GLP-1 analog
Semaglutide has become one of the most studied peptide compounds due to its interaction with GLP1 receptors and its relevance in metabolic regulation and cellular signaling studies
You're not being difficult